Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.2 million.

  • Arrowhead Pharmaceuticals' Consolidated Net Income rose 11611.82% to $28.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $233.5 million, marking a year-over-year increase of 13595.3%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Consolidated Net Income stood at $28.2 million, which was up 11611.82% from $16.1 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Consolidated Net Income peaked at $367.8 million during Q1 2025, and registered a low of -$178.7 million during Q2 2025.
  • For the 5-year period, Arrowhead Pharmaceuticals' Consolidated Net Income averaged around -$52.9 million, with its median value being -$67.7 million (2021).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 36637.3% in 2024, then skyrocketed by 38962.8% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$62.9 million in 2021, then skyrocketed by 33.5% to -$41.8 million in 2022, then plummeted by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then skyrocketed by 116.12% to $28.2 million in 2025.
  • Its Consolidated Net Income stands at $28.2 million for Q4 2025, versus $16.1 million for Q3 2025 and -$178.7 million for Q2 2025.